249 related articles for article (PubMed ID: 33777359)
1. Novel non-cystic features of polycystic kidney disease: having new eyes or seeking new landscapes.
Van Laecke S; Van Biesen W
Clin Kidney J; 2021 Mar; 14(3):746-755. PubMed ID: 33777359
[TBL] [Abstract][Full Text] [Related]
2. Advances in Autosomal Dominant Polycystic Kidney Disease: A Clinical Review.
Nobakht N; Hanna RM; Al-Baghdadi M; Ameen KM; Arman F; Nobahkt E; Kamgar M; Rastogi A
Kidney Med; 2020; 2(2):196-208. PubMed ID: 32734239
[TBL] [Abstract][Full Text] [Related]
3. TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
Olalekan K; Fox A; Gilbert R
Arch Dis Child; 2016 Sep; 101(9):e2. PubMed ID: 27540244
[TBL] [Abstract][Full Text] [Related]
4. The Jeremiah Metzger Lecture. Polycystic kidney disease: old disease in a new context.
Grantham JJ
Trans Am Clin Climatol Assoc; 2002; 113():211-24; discussion 224-6. PubMed ID: 12053711
[TBL] [Abstract][Full Text] [Related]
5. Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease.
Cho Y; Sautenet B; Rangan G; Craig JC; Ong ACM; Chapman A; Ahn C; Chen D; Coolican H; Kao JT; Gansevoort R; Perrone R; Harris T; Torres V; Pei Y; Kerr PG; Ryan J; Gutman T; Howell M; Ju A; Manera KE; Teixeira-Pinto A; Hamiwka LA; Tong A
Trials; 2017 Nov; 18(1):560. PubMed ID: 29169385
[TBL] [Abstract][Full Text] [Related]
6. Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop.
Cho Y; Tong A; Craig JC; Mustafa RA; Chapman A; Perrone RD; Ahn C; Fowler K; Torres V; Gansevoort RT; Ong ACM; Coolican H; Tze-Wah Kao J; Harris T; Gutman T; Shen JI; Viecelli AK; Johnson DW; Au E; El-Damanawi R; Logeman C; Ju A; Manera KE; Chonchol M; Odland D; Baron D; Pei Y; Sautenet B; Rastogi A; Sharma A; Rangan G;
Am J Kidney Dis; 2021 Feb; 77(2):255-263. PubMed ID: 32771648
[TBL] [Abstract][Full Text] [Related]
7. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
[TBL] [Abstract][Full Text] [Related]
8. Autosomal dominant polycystic kidney disease: Disrupted pathways and potential therapeutic interventions.
Malekshahabi T; Khoshdel Rad N; Serra AL; Moghadasali R
J Cell Physiol; 2019 Aug; 234(8):12451-12470. PubMed ID: 30644092
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of transcription factor profiles in polycystic kidney disease (PKD): identification and validation of STAT3 and RUNX1 in the injury/repair response and PKD progression.
Formica C; Malas T; Balog J; Verburg L; 't Hoen PAC; Peters DJM
J Mol Med (Berl); 2019 Dec; 97(12):1643-1656. PubMed ID: 31773180
[TBL] [Abstract][Full Text] [Related]
10. Emerging Therapies for Childhood Polycystic Kidney Disease.
Sweeney WE; Avner ED
Front Pediatr; 2017; 5():77. PubMed ID: 28473970
[TBL] [Abstract][Full Text] [Related]
11. Animal models for human polycystic kidney disease.
Nagao S; Kugita M; Yoshihara D; Yamaguchi T
Exp Anim; 2012; 61(5):477-88. PubMed ID: 23095811
[TBL] [Abstract][Full Text] [Related]
12. Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
Smith KA; Thompson AM; Baron DA; Broadbent ST; Lundstrom GH; Perrone RD
Am J Kidney Dis; 2019 Apr; 73(4):533-541. PubMed ID: 30600104
[TBL] [Abstract][Full Text] [Related]
13. [Pathophysiology, epidemiology, clinical presentation, diagnosis and treatment options for autosomal dominant polycystic kidney disease].
Noël N; Rieu P
Nephrol Ther; 2015 Jul; 11(4):213-25. PubMed ID: 26113401
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathogenesis of autosomal dominant polycystic kidney disease.
Yoder BK; Mulroy S; Eustace H; Boucher C; Sandford R
Expert Rev Mol Med; 2006 Jan; 8(2):1-22. PubMed ID: 16515728
[TBL] [Abstract][Full Text] [Related]
15. Polycystic kidney disease--the ciliary connection.
Ong AC; Wheatley DN
Lancet; 2003 Mar; 361(9359):774-6. PubMed ID: 12620752
[TBL] [Abstract][Full Text] [Related]
16. Autosomal dominant polycystic kidney disease (ADPKD, MIM 173900, PKD1 and PKD2 genes, protein products known as polycystin-1 and polycystin-2).
Boucher C; Sandford R
Eur J Hum Genet; 2004 May; 12(5):347-54. PubMed ID: 14872199
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in management of autosomal-dominant polycystic kidney disease.
Potts JW; Mousa SA
Am J Health Syst Pharm; 2017 Dec; 74(23):1959-1968. PubMed ID: 29167138
[TBL] [Abstract][Full Text] [Related]
18. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.
Brosnahan GM; Abebe KZ; Rahbari-Oskoui FF; Patterson CG; Bae KT; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Perrone RD; Steinman TI; Torres VE;
Curr Hypertens Rev; 2017; 13(2):109-120. PubMed ID: 28460625
[TBL] [Abstract][Full Text] [Related]
19. Polycystic kidney disease.
Bergmann C; Guay-Woodford LM; Harris PC; Horie S; Peters DJM; Torres VE
Nat Rev Dis Primers; 2018 Dec; 4(1):50. PubMed ID: 30523303
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
